TSHA vs VYGR
TSHA: Taysha Gene Therapies is a clinical-stage biotechnology company developing AAV-based gene therapies for rare, monogenic central nervous system disorders. VYGR: Voyager Therapeutics is a gene therapy company utilizing its proprietary TRACER AAV platform to develop intravenous, brain-penetrant treatments for severe neurological diseases.
Side-by-side fundamentals
| Metric | TSHA | VYGR | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $4.43 | $2.37 | |
| Market cap | $1.4B | $146M | |
| Net margin FY2025, SEC XBRL | -1115.3% | -296.5% | VYGR higher |
| Operating margin FY2025, SEC XBRL | -1130.6% | -326.6% | VYGR higher |
| ROE FY2025, SEC XBRL | -44.1% | -61.1% | TSHA higher |
| ROA FY2025, SEC XBRL | -31.7% | -47.5% | TSHA higher |
| Debt / equity as of 2026-09-02 | 0.23 | 0.00 | VYGR lower |
| Revenue growth (YoY) as of 2026-09-02 | +3.4% | -19.1% | TSHA higher |
| Revenue CAGR (3y) SEC XBRL | +57.5% | -0.4% | TSHA higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 1.29 | 1.41 | |
| 1-year return as of 2026-10-08 close | -12.5% | -55.1% | TSHA higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.